The sulfonylurea controversy: Much ado about nothing or cause for concern?

Journal of the American College of Cardiology

Volumn 42, Issue 6, 2003, Pages 1022-1025

  Brady, Peter A ^a   Jovanovic, Aleksandar ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE KINASE; INSULIN; PHENFORMIN; POTASSIUM CHANNEL; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ELECTROCARDIOGRAM; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; ST SEGMENT ELEVATION;

EID: 0041733916     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00897-0     Document Type: Editorial

References (32)

1. Brown SDJ, Landry FJ. Recognizing, reporting, and reducing adverse drug reactions. South Med J 2001;94:370-3.
2. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20 to 74 years. Diabetes 1987;36:523-54.
3. Wingard DE, Barrett-Connors E. Heart Disease and Diabetes. 2nd edition. Bethesda, MD: National Institutes of Health, 1995.
4. National Diabetes Information Clearing House. Washington, DC: NIH Publications 1999:99-3926.
5. Wahab NN, Cowden EA, Pearce NJ, Gardner MJ, Merry H, Cox JL. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol 2002;40:1748-54.
6. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99:2626-32.
7. Klimt CR, Knatterud GL, Meinert CL, Prout TE. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes (UGDP). Diabetes 1970;19:747-830.
8. + channel in cardiac muscle. Nature 1983;305:147-8.
9. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998;31:950-6.
10. 2+ loading in cardiomyocytes. Eur J Pharmacol 1996;308:343-9.
11. + channel subunits confer resistance towards chemical hypoxia-reoxygenation injury. Circulation 1998;98:1548-55.
12. 2+ loading in single cardiomyocytes exposed to metabolic stress. Int J Mol Med 2001;7:639-43.
13. Carrasco AJ, Dzeja PP, Alekseev AE, et al. Adenylate kinase phosphotransfer communicates cellular energetic signals to ATP-sensitive potassium channels. Proc Natl Acad Sci USA 2001;98:7623-8.
14. + channel in vivo. FASEB J 2002;16:102-4.
15. Crawford RM, Budas GR, Jovanovic S, et al. M-LDH serves as a sarcolemmal KATP channel subunit essential for cell protection against ischemia. EMBO J 2002;21:3936-48.
16. Zingman LV, Hodgson DM, Bast PH, et al. Kir6.2 is required for adaptation to stress. Proc Natl Acad Sci USA 2002;99:13278-83.
17. + channel on ECG ST-segment elevation during a bout of myocardial ischemia. A study on epicardial mapping in dogs. Circulation 1993;88:1845-51.
18. + channel blocker. Circulation 1994;90:700-5.
19. ATP channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest 2002;109:509-16.
20. Huizar JF, Gonzalez LA, Alderman J, Smith HS. Sulfonylureas attenuate electrocardiograpbic ST-segment elevation during an acute myocardial infarction in diabetics. J Am Coll Cardiol 2003;42:1017-21.
21. + channels. J Am Coll Cardiol 2001;38:906-15.
22. + channels in a gender-dependent manner. Mech Ageing Dev 2002;123:695-705.
23. Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997;30:171-9.
24. Mak KH, Topol EJ. Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus. J Am Coll Cardiol 2000;35:563-8.
25. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
26. Brady PA, Al-Suwaidi J, Kopecky SL, Terzic A. Sulfonylureas and mortality in diabetic patients after myocardial infarction. Circulation 1998;97:709-10.
27. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DRJ. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33:119-24.
28. ATP channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol 2002;40:1339-46.
29. ATP channel opening in patches from guinea-pig cardiomyocytes. J Physiol (Lond) 1996;492:395-404.
30. + channels towards sulfonylureas. Circ Res 1998;82:272-8.
31. Jovanovic S, Jovanovic A. Diadenosine tetraphosphate-gating of cardiac KATP channels requires intact actin cytoskeleton. Naunyn Schmiedebergs Arch Pharmacol 2001;364:276-80.
32. Fath-Ordoubadi F, Keatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction. An overview of randomized placebo-controlled trials. Circulation 1997;96:1152-6.